RxDoctor Payments Data

Jon Berry, MD

Ophthalmology · Oklahoma City, OKNPI 1558867143

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,532 of the $2,069 with a category attached, or 74.0%. 13 manufacturers reported payments, led by Alcon at 36.6% of the total. 2025 is the largest year on record at $603, 2.8 times the $213 reported in 2019.

$2,069in general payments, 2019–2025

Across 40 payments — averaging $51.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$757
  • Biotissue Holdings Inc.$437
  • AbbVie$330
  • Glaukos Corporation$158
  • Nova Eye, Inc.$105
  • Carl Zeiss Meditec USA, Inc.$93
  • plus $189 from 7 others

What the payments were for

  • Travel & lodging$43721%
  • Food & beverage$1,53274%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,069 in reported general payments places this provider in the 65th percentile of 183 ophthalmology providers in Oklahoma.

See all ophthalmology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$175,322
Medicare patients
415
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost29$16,984
RestasisCyclosporine12$16,631
Prednisolone Acetate277$15,236
RhopressaNetarsudil Mesylate34$13,361
RocklatanNetarsudil Mesylat/Latanoprost15$10,919
MoxifloxacinMoxifloxacin Hcl279$8,099
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$5,538
Timolol Maleate107$5,492
VyzultaLatanoprostene Bunod12$4,901
IyuzehLatanoprost/Pf12$3,524
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat223$3,313
Latanoprost271$3,245
Ketorolac Tromethamine84$2,892
Brimonidine Tartrate120$2,503
Timolol MaleateTimolol Maleate/Pf11$2,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$330$33,61541 claims
Bausch & Lomb Americas Inc.Vyzulta$55$4,90112 claims
Thea Pharma Inc.Iyuzeh$18$3,52412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 183 ophthalmology providers in Oklahoma.

Other ophthalmology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →